Catalyst Wire Dossier Catalyst Wire Dossier

Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy)

bictegravir/emtricitabine/tenofovir alafenamide · Gilead Sciences
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy), covering 2026-04-20 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646) [Phase 1]

See pricing